Takeda Announces European Commission Approval Of FRUZAQLA (Fruquintinib) For Treatment Of Metastatic Colorectal Cancer In Adults Previously Treated With Standard Therapies; Approval Follows CHMP Opinion And Previous FDA Approval
Author: Benzinga Newsdesk | June 21, 2024 04:00pm
− Approval Based on Results from Positive, Global, Phase 3 FRESCO-2 Trial− FRUZAQLA (fruquintinib) is the First Novel Targeted Therapy in the EU for Metastatic Colorectal Cancer (mCRC) Regardless of Biomarker Status in
− Approval Based on Results from Positive, Global, Phase 3 FRESCO-2 Trial
− FRUZAQLA (fruquintinib) is the First Novel Targeted Therapy in the EU for Metastatic Colorectal Cancer (mCRC) Regardless of Biomarker Status in Over a Decade
Posted In: HCM TAK VGK